{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-009994","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.808340+00:00","generated_at":"2026-05-16T05:10:07.908773+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42","bullets":["GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.","Protein Sciences segment revenue +2% to $215.1M; operating margin fell to 39.3% from 41.2%.","Diagnostics & Spatial Biology segment revenue -4% to $81.2M; organic growth +3% with margin up to 10.4%.","Board declares $0.08/share quarterly dividend, payable Feb 27, 2026 to holders of record Feb 16, 2026.","China/APAC region drove growth for third consecutive quarter; large pharma end-market grew double digits."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-009994","json":"https://secwatch.observer/filing/0001104659-26-009994.json","markdown":"https://secwatch.observer/filing/0001104659-26-009994.md","text":"https://secwatch.observer/filing/0001104659-26-009994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/0001104659-26-009994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/tech-20260204x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:10:07.908773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}